Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus famitinib for advanced genitourinary and gynecologic cancers
CTR20191816Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Jan 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, famitinib in genitourinary cancer, gynecological cancer, sponsored by Hengrui Therapeutics. Started Jan 2019; status: active.
02
Drugs
camrelizumabfamitinib
03
Conditions
genitourinary cancergynecological cancer
Beyond the preview
Go deeper on CTR20191816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191816.